Annual report pursuant to Section 13 and 15(d)

Income Taxes (Details Narrative)

v3.19.3.a.u2
Income Taxes (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Mar. 19, 2018
Deferred tax liability       $ 3,037,147
Intangible assets, financial reporting basis       11,038,929
Intangible assets, tax basis       $ 1,782
Net operating loss before income tax benefit $ (3,960,592) $ (4,667,848)    
Income tax benefit $ (602,716) (902,801) $ 258,583  
Income tax effected rate amount     $ 71,283  
Net operating loss carryforward term P20Y      
Net operating loss carryforward, expiration date 2037      
Change in valuation of allowance $ 668,584 329,755    
Deferred tax asset, start-up expenditures 2,909,715 1,703,904    
Deferred tax asset, loss carryforwards 4,067,602 2,665,796    
Deferred tax asset, start-up expenditures, tax effected 800,681 468,872    
Deferred tax asset, loss carryforwards, tax effected 1,119,302 $ 733,560    
Tax Cuts and Jobs Act [Member]        
Income tax description   On December 22, 2017, the Tax Cuts and Jobs Act of 2017 ("TCJA") was signed into law. Among its provisions, the TCJA reduces the statutory U.S. Corporate income tax rate from 34% to 21% effective January 1, 2018.    
Federal [Member]        
Net operating loss carryforward 1,400,000 $ 2,400,000    
Federal net operating loss carryforward 4,100,000 2,700,000    
Deferred tax loss carryforward 6,977,317 4,369,700    
Orphan Drug [Member]        
Income tax benefit 283,189      
Deferred tax loss carryforward 283,189      
General and Administrative [Member]        
Income tax benefit 1,205,811 1,356,840    
Income tax effected rate amount $ 331,809 $ 373,368